About Us
Back
Leadership
Board of Directors
Investors
Scientific Advisory Board
Technology
Back
Integrin Biology
The Journey to Oral Integrins
MInT Platform and Strategy
Pipeline
Investors
Careers
Contact Us
PRAVEEN TIPIRNENI (CEO): What Surprised You Most in Series A Fundraising
Recent Posts
Morphic Therapeutic Appoints Former Gilead Leader Norbert Bischofberger, Ph.D., to Board of Directors
Morphic Therapeutic Enters Into Integrin Research and Development Collaboration with Janssen
Morphic Therapeutic to Present at 37th Annual J.P. Morgan Healthcare Conference
AbbVie and Morphic Therapeutic Announce Collaboration Targeting Fibrotic Diseases
Morphic Therapeutic Announces $80 Million Financing to Advance Next-Generation Oral Integrin Therapeutics through Clinical Proof of Concept
Categories
HiPO Employee
Industry News
Morphic Therapeutic
Press Release
Uncategorized
Search for: